Compare Endeavour Silver Corp (EXK) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Endeavour Silver Corp vs Sana Biotechnology Inc — how do they compare? Endeavour Silver Corp trades at $8.66 (market cap $2.54B), while Sana Biotechnology Inc trades at $2.8 (market cap $836.71M). The key difference: Endeavour Silver Corp is far larger — about 3× Sana Biotechnology Inc's market cap, and Endeavour Silver Corp is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Endeavour Silver Corp for 25 Days and Sana Biotechnology Inc for 23 Days on average.
| EXK | SANA | |
|---|---|---|
Market Cap | $2.54B | $836.71M |
Volume | 7,077,330 | 4,507,444 |
Sector | Basic Materials | Health |
52-Week High | $14.12 | $5.92 |
52-Week Low | $7.07 | $2.68 |
Typical Hold Time | 25 Days | 23 Days |
Enterprise Value | $2.54B | $749.96M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Endeavour Silver (EXK) trades at $8.65, up 3.97% today. The technical outlook is bearish, with moving averages signaling a downtrend, while fundamentals show a transition from a net loss in 2025 to a projected profit in 2026. Recent news highlights operational progress at the Terronera and Kolpa mines, though temporary disruptions occurred. Analyst sentiment is strongly positive, with 78.57% recommending Buy.
The stock presents a growth opportunity driven by mine expansions and favorable silver prices, but faces risks from operational hiccups and high valuation multiples. Investors should weigh the bullish analyst consensus against execution risks and market volatility for silver equities.
SANA Biotechnology trades at $2.84, up 4.41% today, while showing bearish technical signals with moving averages indicating selling pressure. The company remains pre-revenue with significant losses (-$244.17M net income in 2025) and negative cash flow from operations. Recent investor conference presentations highlight ongoing development of engineered cell therapies, though earnings have missed expectations in two of the last three quarters.
Despite analyst optimism (82% buy ratings), SANA faces substantial execution risk as a clinical-stage biotech with no current revenue and high cash burn. The stock's outlook depends heavily on clinical trial progress and future funding needs, with current valuation at 5.41x book value despite negative profitability metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Endeavour Silver Corp
Endeavour Silver is a mid-tier precious metals mining company. It operates silver-gold mines in Mexico and is focused on growing its production and reserves through exploration and the development of new mining projects.
Read more on EXK →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
